Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has announced the pricing of a public offering. The company plans to sell 8,106,584 shares of common stock (or pre-funded warrants) at $0.55 per share. The offering is expected to close around September 5, 2024, with anticipated gross proceeds of $4.45 million. Oragenics intends to use the net proceeds to fund the development of its ONP-002 product candidate and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent for this offering, which is being made pursuant to an effective registration statement filed with the SEC.
Oragenics, Inc. (NYSE American: OGEN), un'azienda che sviluppa farmaci intranasali per disturbi neurologici, ha annunciato il prezzo di un'offerta pubblica. L'azienda prevede di vendere 8.106.584 azioni di azioni ordinarie (o warrant pre-finanziati) a 0,55 $ per azione. Si prevede che l'offerta si chiuda intorno al 5 settembre 2024, con proventi lordi attesi di 4,45 milioni di dollari. Oragenics intende utilizzare i proventi netti per finanziare lo sviluppo del suo candidati prodotto ONP-002 e per scopi aziendali generali. Dawson James Securities, Inc. funge da unico agente di collocamento per questa offerta, che viene effettuata ai sensi di una registrazione efficace depositata presso la SEC.
Oragenics, Inc. (NYSE American: OGEN), una empresa que desarrolla productos farmacéuticos intranasales para trastornos neurológicos, ha anunciado el precio de una oferta pública. La compañía planea vender 8,106,584 acciones de acciones ordinarias (o warrants prefinanciados) a $0.55 por acción. Se espera que la oferta cierre alrededor del 5 de septiembre de 2024, con ingresos brutos anticipados de $4.45 millones. Oragenics tiene la intención de utilizar los ingresos netos para financiar el desarrollo de su candidato a producto ONP-002 y para propósitos corporativos generales. Dawson James Securities, Inc. actúa como el único agente de colocación para esta oferta, que se realiza conforme a una declaración de registro efectiva presentada ante la SEC.
Oragenics, Inc. (NYSE American: OGEN)는 신경 장애를 위한 비강 약물을 개발하는 회사로, 공모의 가격을 발표했습니다. 이 회사는 8,106,584 주식의 보통주 (또는 사전 자금 조달된 워런트)를 주당 0.55달러에 판매할 계획입니다. 이 공모는 2024년 9월 5일 경에 종료될 것으로 예상되며, 예상 총수익은 445만 달러입니다. Oragenics는 순수익을 사용하여 ONP-002 제품 후보의 개발을 지원하고 일반 기업 목적을 위해 사용할 계획입니다. Dawson James Securities, Inc.는 이 공모의 단독 배치 에이전트로 활동하며, 이는 SEC에 제출된 유효한 등록명세서에 따라 이루어집니다.
Oragenics, Inc. (NYSE American: OGEN), une entreprise développant des médicaments intranasaux pour les troubles neurologiques, a annoncé le prix d'une offre publique. La société prévoit de vendre 8 106 584 actions d'actions ordinaires (ou warrants préfinancés) à 0,55 $ par action. L'offre devrait se terminer vers le 5 septembre 2024, avec un produit brut anticipé de 4,45 millions de dollars. Oragenics entend utiliser les produits nets pour financer le développement de son candidat produit ONP-002 et pour des fins commerciales générales. Dawson James Securities, Inc. agit en tant qu'agent de placement unique pour cette offre, qui est réalisée conformément à une déclaration d'enregistrement efficace déposée auprès de la SEC.
Oragenics, Inc. (NYSE American: OGEN), ein Unternehmen, das intranasale Arzneimittel für neurologische Erkrankungen entwickelt, hat die Preisgestaltung für ein öffentliche Angebot bekannt gegeben. Das Unternehmen plant, 8.106.584 Aktien von Stammaktien (oder vorfinanzierten Warrants) zu einem Preis von 0,55 $ pro Aktie zu verkaufen. Das Angebot soll voraussichtlich um den 5. September 2024 abgeschlossen werden, mit erwarteten Bruttoeinnahmen von 4,45 Millionen Dollar. Oragenics beabsichtigt, die Nettoerlöse zur Finanzierung der Entwicklung seines Produktkandidaten ONP-002 sowie für allgemeine Unternehmenszwecke zu verwenden. Dawson James Securities, Inc. fungiert als alleiniger Platzierungsagent für dieses Angebot, das gemäß einer gültigen Registrierungserklärung, die bei der SEC eingereicht wurde, durchgeführt wird.
- Raising approximately $4.45 million in gross proceeds
- Funds to be used for development of ONP-002 product candidate
- Successful pricing of public offering indicates market interest
- Potential dilution of existing shareholders' ownership
- Offering price of $0.55 per share may be below current market price
- Additional expenses related to placement agent fees and offering costs
Insights
Oragenics' public offering of
The
The offering's compliance with SEC regulations, including the effective S-1 registration and detailed prospectus, demonstrates Oragenics' adherence to legal requirements. However, the inclusion of a safe harbor statement in the press release is notably absent, which is unusual for forward-looking statements about fund usage and closing conditions. The company's use of a placement agent rather than an underwriter suggests a best efforts offering, potentially indicating challenges in securing firm commitments. Investors should carefully review the full prospectus for risk factors and exact terms of the pre-funded warrants, as these could have significant legal and financial implications.
SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of
The gross proceeds of the offering are anticipated to be approximately
Dawson James Securities, Inc. is acting as the sole placement agent for the offering.
The offering is being made pursuant to a registration statement on Form S-1 (File No. 333-281618), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 16, 2024, and declared effective on September 3, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432, or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering, which will provide more information about Oragenics and the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including those relating to the completion of the public offering, the satisfaction of customary closing conditions, the intended use of proceeds from the public offering and other statements that are predictive in nature. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
FAQ
What is the purpose of Oragenics' (OGEN) public offering announced on September 4, 2024?
How many shares is Oragenics (OGEN) offering in its September 2024 public offering?
What is the price per share for Oragenics' (OGEN) September 2024 public offering?
When is the expected closing date for Oragenics' (OGEN) September 2024 public offering?
